Download Stanford Profiles: /viewBiosketch

FF
Principal Investigator/Program Director (Last, first, middle):
Katzenstein, David A.
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel in the order listed for Form Page 2.
Photocopy this page or follow this format for each person.
NAME
David Katzenstein
POSITION TITLE
Associate Professor of Medicine
Associate Director, Stanford ACTU
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include
postdoctoral training.)
INSTITUTION AND LOCATION
University of California, San Diego, San Diego, CA
University of California, San Diego School of Medicine
University of California, San Diego
University of California, Davis, Davis, CA
DEGREE
(if applicable)
YEAR(s)
B.A.
M.D.
1973
1977
1980
1983
FIELD OF STUDY
Biology
Medicine
Fellowship/ID
Fellowship/ID
RESEARCH AND PROFESSIONAL EXPERIENCE:
A. Positions and Honors.
Positions and Employment
1982-1984
Assistant Clinical Professor of Medicine, Division of Infectious Disease, University of California, Davis and
Martinez Veterans Administration Hospital, Martinez, CA.
1982-1984
Assistant Professor of Medicine, Division of Infectious Diseases, University of Minnesota.
1986-1987
Lecturer, Department of Medical Microbiology, Godfrey Huggins School of Medicine, University of Zimbabwe.
1987-1989
Senior Research Fellow, Laboratory of Retrovirus Research, Center for Biologics Evaluation and Research, Food
and Drug Administration.
1989-1990
Clinical Assistant Professor of Medicine, Division of Infectious Diseases, Stanford
University, and Associate Director, Stanford University AIDS Clinical Trials Group.
1990-1997
Assistant Professor of Medicine, Division of Infectious Diseases, Stanford University, and Associate Medical
Director, Stanford University AIDS Clinical Trials Group.
1997-present Associate Professor of Medicine, Division of Infectious Diseases, Stanford University
Other Experience and Professional Memberships
1992- present Associate Director, Stanford University AIDS Clinical Trials Group.
1992 -1996
Associate Director, Stanford Clinical Virology Laboratory
1996- present Director, Stanford University Advanced Technology Laboratory
1995-2000
Member, HIV Disease Research Agenda Committee, ACTG
1995-2001
Member, University of California Universitywide Task Force on AIDS
1999-2002
Chair, HIV Resistance Web Board of Scientific Advisors
2000- present Chair, Biologic Outcome working Group, NIMH C-pol study
1996 International AIDS Society – USA antiretroviral panel
1988 Infectious Disease Society of America
2001HIV Medicine Association
2001
Rockefeller AIDS Care and Treatment Antiretroviral Working Group
2001
International Physicians in AIDS Care, faculty
Honors
2000
Doris Duke Charitable Foundation , Distinguished Clinical Scientist Award
PHS 398 (REV. 5/95)
(Form Page 6) Page
Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b.
FF
SELECTED BIBLIOGRAPHY
1. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T,
Reichman R, Japour A, Merigan TC. The relation of virologic and immunologic markers to clincial outcomes
after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per millimeter. AIDS Clinical Trials
Group Study 175 Virology Study Team. New England J. Med, 1996; 335 (15): 1091-8.
2. Goulston C, McFarland W, Katzenstein DA. Human immunodeficiency virus type 1 RNA shedding in the
female genital tract. Journal of Infectious Diseases, 1998; 177 (4): 1100-1103.
3. Rey D, Hughes M, Pi JT, Winters M, Merigan TC, Katzenstein DA. HIV-1 reverse transcriptase codon 215
mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group
175 Virology Team. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 1998; 17
(3): 203-208.
4. Zijenah L, Mbizvo MT, Kasule J, Nathoo K , Munjoma M, K, Mahomed K , Maldonado Y, Madzime S, and
Katzenstein D. Mortality in the first 2 years among infants born to HIV-infected women in Harare, Zimbabwe.
Journal of Infectious Diseases, 1998; 178 (1):109-113.
5. Simpson D, Katzenstein DA, Hughes MD, Hammer SM, Williamson DL, Jiang Q, Pi JT. Neuromuscular
function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical
Group 175/801 Study Team. AIDS, 1998; 12 (18): 2425-2432.
6. Winters MA,Coolley KL, Girard YA, Levell DJ, Hamdan H, Shafer RW, Katzenstein DA, Merigan TC. A 6basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to
multiple nucleoside inhibitors. J Clin Invest, 1998; 102 (100: 1769-75.
7. Gregson S, Machekano R, Donnell CA, Mbizvo MT, Anderson RM, Katzenstein DA. Estimating HIV
incidence from age-specific prevalence data: comparison with concurrent cohort estimates in a study of male
factory workers, Harare, Zimbabwe. AIDS, 1998; 12 (15): 2049-58.
8. Marschener IC, Collier AC, Coombs RW, D'Aquilla RT, DeGruttola V, Fishcl MA, Hammer SM, Hughes MD,
Johnson VA, Katzenstein DA, Richman DD, Smeaton LM, Spector SA, Saag MS. Use of changes in plasma
levels of human immunodeficiency virus type 1 RNA to assess clinical benefit of antiretroviral therapy. J
Infect Dis, 1998; 177 (1): 40-47.
9. Lathey JL, Hughes MD, Fiscus SA, Pi T, Jackson JB, Rasheed S, Elbeik T, Reichman R, Japour A, D'Aquila
RT, Scott W, Griffith BP, Hammer SM, Katzenstein DA. Variability and prognostic values of virologic and
CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3)
(ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis, 1998; 177 (3): 617-624.
10. Watts H, Spino C, Zaborski L, Katzenstein D, Hammer S, Benson C. Comparison of gynecologic findings in
HIV positive women with CD4 counts between 200 and 500 and below 100. JAIDS, 20 (5): 455-62, 1999.
11. Shafer RW, Chaung T, Hsu P, White CB, Katzenstein DA. Sequence and drug susceptibility of subtype C
protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe, AIDS Res Hum Retro,
1999; 15 (1): 65-69.
12. Tien PC, Chiu T, Latif A, Ray S, Batra M, Contag CH, Zejenah L, Mbizvo M, Delwart EL, Mullins JI,
Katzenstein DA. Primary Subtype C HIV-1 Infection in Harare, Zimbabwe. J Acquired Imm Def Syndr Hum
Retro 1999; 20 (2): 147-153.
13. Katzenstein D, Mbizvo M, Zijeneh L, Gittens T, Munjoma M, Hill D, Madzime S, and Maldonado Y. Serum
level of maternal human immunodeficiency virus (HIV) RNA, infant mortality, and vertical transmission of
HIV in Zimbabwe. Journal of Infectious Diseases, 1999; 179 (6): 1382-1387.
14. Shulman NS, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein DA, Israelski DM, Hellmann N,
Petropoulos C, Whitcomb J. Phenotypic hyper-susceptibility of non-nucleoside reverse transcriptase inhibitors
in treatment experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
AIDS. 2001 Jun 15;15(9):1125-32.
PHS 398 (REV. 5/95)
(Form Page 6) Page
Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b.
FF
15. J. Lathey, C. Tierney, S. Chang, R. D’aquila, D. Bettendorf, H. Alexander, C. Santini, A. Hughes, C. Barroga,
S. Spector, J. Landes, S. Hammer, D. Katzenstein, and the ACTG 175 Virology Team* for the AIDS Clinical
Trials Group, NIAID, Bethesda, MD. Associations of CCR5, CCR2, and SDF-1 Genotypes with Disease
Progression and Response to ARVs in Asymptomatic Patients in ACTG 175. J Infect Dis 2001; 184:1402-11.
16. Shulman, NS, Shafer RA, Winters M, Machekano R, Zolopa AR, Hughes M, Katzenstein DA Genotypic
correlates of a virologic response to stavudine after zidovudine monotherapy. J Acquir Immune Defic Syndr.
2001 Aug 1;27(4):377-80.
17. Albrecht MA, Bosch R, Hammer S, Liou S-H, Kessler H, Para M, Eron J, Valdez H, Dehlinger M,
Katzenstein DA. Nelfinavir, Efavirenz or both after failure of nucleoside treatment of HIV infection. New
Engl J Med 2001;345:398-407
18. Simpson DM, Katzenstein DA, Haidich AB, Schifitto G, Yiannoutsos CT, Geraci AP, McArthur JC, ACTG
291 study team. Severity of symptoms of DSPN related to HIV-1 RNA plasma viral load Neurology 2001.
19. Albrecht MA, Bosch R, Hammer S, Liou S-H, Kessler H, Para M, Eron J, Valdez H, Dehlinger M,
Katzenstein DA. Nelfinavir, Efavirenz or both after failure of nucleoside treatment of HIV infection. New
Engl J Med 2001;345:398-407.
20. Miriam Rabkin, Wafaa El-Sadr, David Katzenstein, Kevin M. De Cock, Joia Mukherjee, Henry Masur, Peter
Mugyenyi, Paula Munderi and Janet Darbyshire. Antiretroviral therapy in resource-poor settings: Clinical
research priorities. Lancet 2002; 360: 1503–05.
21. D. A. Katzenstein1, R. J. Bosch, N Hellmann3, N Wang2, L Bacheler4, M. A. Albrecht. Phenotypic
Susceptibility And Virologic Outcome In Nucleoside-Experienced Patients Receiving Three Or Four
Antiretrovirals. AIDS 2003; 17:821-830.
22. Mark A.Winters, Ronald J. Bosch, Mary A. Albrecht, and David A. Katzenstein for the ACTG 364 Study
Team Clinical Impact of the M184V Mutation on Switching to Didanosine or Maintaining Lamivudine
Treatment in Nucleoside-Experienced Patients. J Infect Dis. 2003 Aug 15;188(4):537-40.
23. Rami Kantor, Solomon Mutetwa, Lynn Zijenah, Elizabeth Johnston, Robert Lloyd, Andrea von Lieven, Dennis
Israelski, Robert W. Shafer and David A. Katzenstein. HIV-1 subtype C reverse transcriptase and protease
genotypes in patients from Zimbabwe failing ARV Aids Research And Human Retro 2002; 18: 1407–1413.
24. Camlin Tierney, Janet L. Lathey, Cindy Christopherson, Daniel M. Bettendorf, Richard T. D'Aquila, Scott M.
Hammer, David A. Katzenstein, and the ACTG 175 Virology Team . Prognostic Value of Baseline HIV-1
DNA Measurement for HIV Disease Progression in Patients Receiving Nucleoside Therapy. Journal of
Infectious Diseases 2003; 187:144–8.
25. Kantor R, Katzenstein D.Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its
potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 2003 Jan-Mar;5(1):25-35.
26. Elizabeth R. Johnston, Lynn S. Zijenah, Solomon Mutetwa, Rami Kantor, Chonticha Kittinunvorakoon, and
David A. Katzenstein. High Frequency of Syncytia inducing and CXCR4 tropic viruses among HIV-1 Subtype
C infected patients receiving antiretroviral treatment. J Virol 2003;77(13):7682-8.
27. Ronald J. Bosch; Gerald F. Downey; David A. Katzenstein; Nicholas Hellmann; Lee Bacheler; Mary A.
Albrecht; for the ACTG 364 Study Team.Evaluation of cutpoints for phenotypic hypersusceptibility to
efavirenz. AIDS 17 (research notes): 2395-2396; Apr 2003
28. Mark A.Winters, Ronald J. Bosch, Mary A. Albrecht, and David A. Katzenstein for the ACTG 364 Study
Team Clinical Impact of the M184V Mutation on Switching to Didanosine or Maintaining Lamivudine
Treatment in Nucleoside-Experienced Patients. J Infect Dis. 2003 Aug 15;188(4):537-40.
29. Jiang H, Deeks SG, Kuritzkes DR, Lallemant M, Katzenstein D, Albrecht M, DeGruttola V. Assessing
resistance costs of ARV therapies via measures of future drug options. J Infect Dis. 2003 Oct 1;188(7):1001-8.
30. Courtney V. Fletcher, Hongyu Jiang,Richard C. Brundage, Edward P. Acosta, Richard Haubrich, David
Katzenstein,Roy M. Gulick. Sex Differences in Saquinavir Pharmacology and Virologic Response in AIDS
Clinical Trials Group (ACTG) Study 359. The Journal of Infectious Diseases 2004;189:1176-1184.
PHS 398 (REV. 5/95)
(Form Page 6) Page
Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b.
FF
PHS 398 (REV. 5/95)
(Form Page 6) Page
Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b.
FF